143007-15-2

Basic information

• Product Name: 2-chloro-6,7-difluoroquinoxaline
• Synonyms: 2-chloro-6,7-difluoroquinoxaline
• CAS NO: 143007-15-2
• Molecular Formula: C₈H₃ClF₂N₂
• Molecular Weight: 200.57
• Product Categories: CHIRAL CHEMICALS
• Mol File: 143007-15-2.mol

Chemical Properties

• Boiling Point: 263℃
• Flash Point: 113℃
• Appearance: /
• Density: 1.538
• Vapor Pressure: 0.017mmHg at 25°C
• Refractive Index: 1.609
• Storage Temp.: 2-8°C
• PKA: -3.15±0.30(Predicted)
• CAS DataBase Reference: 2-chloro-6,7-difluoroquinoxaline(CAS DataBase Reference)
• NIST Chemistry Reference: 2-chloro-6,7-difluoroquinoxaline(143007-15-2)
• EPA Substance Registry System: 2-chloro-6,7-difluoroquinoxaline(143007-15-2)

Safety Data

• Hazardous Substances Data: 143007-15-2(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
2-Chloro-6,7-difluoroquinoxaline is utilized as a key intermediate in the synthesis of pharmaceuticals for its potential biological activities and therapeutic properties. It contributes to the development of new drugs by providing a versatile chemical structure that can be further modified to enhance pharmacological effects and target specific biological pathways.
Used in Agrochemical Industry:
In the agrochemical sector, 2-chloro-6,7-difluoroquinoxaline serves as a valuable building block for the creation of novel agrochemicals. Its unique structure allows for the design of compounds with improved pesticidal properties, such as herbicides, insecticides, and fungicides, which can be tailored to address specific agricultural challenges.
Used in Organic Synthesis:
2-Chloro-6,7-difluoroquinoxaline is employed as a versatile intermediate in organic synthesis, enabling the production of a wide range of organic compounds. Its reactivity and structural features make it suitable for various chemical reactions, facilitating the synthesis of complex molecules with potential applications in various industries.
It is crucial to handle 2-chloro-6,7-difluoroquinoxaline with appropriate safety measures due to its potential hazards. Proper handling, storage, and disposal practices should be followed to minimize risks associated with this chemical compound.

InChI:InChI=1/C8H3ClF2N2/c9-8-3-12-6-1-4(10)5(11)2-7(6)13-8/h1-3H

Upstream product

• 137690-08-5 6,7-difluoroquinoxaline-2-ol 
• 76179-40-3 2-amino-4,5-difluoroaniline 
• 137690-08-5 6,7-difluoroquinoxaline-2(1H)-one 

Downstream Products

• 1030377-40-2 6,7-difluoro-2-{(5R)-5-methyl-4-[2-(2H-1,2,3-triazol-2-yl)benzoyl]-1,4-diazepan-1-yl}quinoxaline 
• 1163123-26-9 C₂₁H₁₇F₅N₄O 
• 1384120-93-7 ((1S,6R)-3-(6,7-difluoroquinoxalin-2-yl)-3,8-diazabicyclo[4.2.0]octan-8-yl)(4-methyl-[1,1'-biphenyl]-2-yl)methanone 
• 476374-15-9 (S)-2-{2-[4-(6,7-Difluoro-quinoxalin-2-ylamino)-phenyl]-acetylamino}-pentanedioic acid diethyl ester 
• 476374-09-1 [4-(6,7-difluoro-quinoxalin-2-ylamino)-phenyl]-acetic acid 
• 709638-76-6 2-ethoxy-6,7-difluoroquinoxaline 
• 709638-28-8 [4-(6,7-difluoro-quinoxalin-2-yloxy)-phenyl]-acetic acid methyl ester 
• 476374-04-6 [4-(6,7-difluoro-quinoxalin-2-ylamino)-phenyl]-acetic acid ethyl ester 

Relevant articles and documents

SUBSTITUTED 2-AZABICYCLO[3.1.1]HEPTANE AND 2-AZABICYCLO[3.2.1]OCTANE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS

There is provided a compound of formula (I), wherein L1 to L3, R1 to R4, X, A and B have meanings given in the description, and pharmaceutically acceptable salts, solvates and prodrugs thereof, which compounds are useful as antagonists of the orexin-1 and orexin-2 receptors or as selective antagonists of the orexin-1 receptor, and thus, in particular, in the treatment or prevention of inter alia substance dependence, addiction, anxiety disorders, panic disorders, binge eating, compulsive disorders, impulse control disorders, cognitive impairment and Alzheimer's disease.

Diarylureaquinoxaline derivative with antitumor activity and synthesis method thereof

The invention discloses a diarylureaquinoxaline derivative with antitumor activity and a synthesis method thereof. According to the technical scheme, the diarylureaquinoxaline derivative is a derivative obtained by taking quinoxaline as a matrix and carrying out appropriate structural modification, and concretely, o-phenylenediamine is taken as a starting material and four steps of reactions arecarried out for substitution and further for adding a fluorine atom and diarylurea, so that the diarylureaquinoxaline derivative with antitumor activity is synthesized. The derivative is an importantheterocyclic compound and has good biological activity. The structural formula of the derivative is shown in the description.

Discovery of Highly Potent Dual Orexin Receptor Antagonists via a Scaffold-Hopping Approach

Starting from suvorexant (trade name Belsomra), we successfully identified interesting templates leading to potent dual orexin receptor antagonists (DORAs) via a scaffold-hopping approach. Structure–activity relationship optimization allowed us not only to improve the antagonistic potency on both orexin 1 and orexin 2 receptors (Ox1 and Ox2, respectively), but also to increase metabolic stability in human liver microsomes (HLM), decrease time-dependent inhibition of cytochrome P450 (CYP) 3A4, and decrease P-glycoprotein (Pgp)-mediated efflux. Compound 80 c [{(1S,6R)-3-(6,7-difluoroquinoxalin-2-yl)-3,8-diazabicyclo[4.2.0]octan-8-yl}(4-methyl-[1,1′-biphenyl]-2-yl)methanone] is a potent and selective DORA that inhibits the stimulating effects of orexin peptides OXA and OXB at both Ox1 and Ox2. In calcium-release assays, 80 c was found to exhibit an insurmountable antagonistic profile at both Ox1 and Ox2, while displaying a sleep-promoting effect in rat and dog models, similar to that of the benchmark compound suvorexant.

HETEROARYL DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS

The present invention relates to compounds of formula wherein Ar, Het, R1 and n are as defined herein and to pharmaceutically suitable acid addition salts, optically pure enantiomers, racemates or diastereomeric mixtures thereof. Compounds of formula I are orexin receptor antagonists and are useful in the treatment of sleep apnea, narcolepsy, insomnia, parasomnia, jet lag syndrome, circadian rhythms disorder and sleep disorders associated with neurological diseases.

Substituted diazepan orexin receptor antagonists

The present invention is directed to substituted diazepan compounds which are antagonists of orexin receptors, and which are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which orexin receptors are involved.

Quinoxaline chemistry. Part XVII. Methyl [4-(substituted 2-quinoxalinyloxy) phenyl] acetates and ethyl N-{[4-(substituted 2-quinoxalinyloxy) phenyl] acetyl} glutamates analogs of methotrexate: Synthesis and evaluation of in vitro anticancer activity

Fourteen out of 21 quinoxaline derivatives described in the present paper were selected at NCI for evaluation of their in vitro anticancer activity. Preliminary screening showed that some derivatives exhibited a moderate to strong growth inhibition activity on various tumor panel cell lines between 10-5 and 10-4 M concentrations. Interesting selectivities were also recorded between 10-8 and 10-6 M for the compounds 9 and 13.